Dapsone-induced haemolysis among leprosy patients on MDT from an endemic area of central India.

IF 1.1 Q4 PRIMARY HEALTH CARE
Krutika P Naik, Satyaki Ganguly, Arvind K Shukla, Namrata Chhabra, Neel Prabha, Ghazal Ahmed
{"title":"Dapsone-induced haemolysis among leprosy patients on MDT from an endemic area of central India.","authors":"Krutika P Naik, Satyaki Ganguly, Arvind K Shukla, Namrata Chhabra, Neel Prabha, Ghazal Ahmed","doi":"10.4103/jfmpc.jfmpc_338_24","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aim: </strong>Haemolysis due to dapsone as a part of MDT in leprosy patients has been long recognized. However, the frequency and severity of this side effect and factors associated with it have not been well documented. We planned to determine the frequency of dapsone-induced haemolysis in leprosy patients on MDT and various risk factors associated with it.</p><p><strong>Materials and methods: </strong>This was a hospital-based retrospective analysis, conducted on 36 treatment completed or partially treated or on treatment leprosy patients in a tertiary care centre in Chhattisgarh.</p><p><strong>Results: </strong>Out of 36 patients, 83.3% showed a fall in haemoglobin from the baseline value (pre-treatment values). Dapsone was stopped in 33.3% of patients with a significant fall in haemoglobin. We found that the mean haemoglobin concentration for all patients fell from 13.05(+/-1.8) g/dl to 11.8(+/-1.9) g/dl (<i>P</i> < 0.05) which was statistically significant. A total of 25% of patients were labelled as confirmed cases of dapsone-induced haemolysis as per our definition.</p><p><strong>Conclusion: </strong>Our results underline the need to incorporate haematological investigations in leprosy management protocol, especially in primary care settings where the majority of leprosy patients are managed.</p>","PeriodicalId":15856,"journal":{"name":"Journal of Family Medicine and Primary Care","volume":"13 9","pages":"3887-3891"},"PeriodicalIF":1.1000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11504738/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Family Medicine and Primary Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jfmpc.jfmpc_338_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/11 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PRIMARY HEALTH CARE","Score":null,"Total":0}
引用次数: 0

Abstract

Background and aim: Haemolysis due to dapsone as a part of MDT in leprosy patients has been long recognized. However, the frequency and severity of this side effect and factors associated with it have not been well documented. We planned to determine the frequency of dapsone-induced haemolysis in leprosy patients on MDT and various risk factors associated with it.

Materials and methods: This was a hospital-based retrospective analysis, conducted on 36 treatment completed or partially treated or on treatment leprosy patients in a tertiary care centre in Chhattisgarh.

Results: Out of 36 patients, 83.3% showed a fall in haemoglobin from the baseline value (pre-treatment values). Dapsone was stopped in 33.3% of patients with a significant fall in haemoglobin. We found that the mean haemoglobin concentration for all patients fell from 13.05(+/-1.8) g/dl to 11.8(+/-1.9) g/dl (P < 0.05) which was statistically significant. A total of 25% of patients were labelled as confirmed cases of dapsone-induced haemolysis as per our definition.

Conclusion: Our results underline the need to incorporate haematological investigations in leprosy management protocol, especially in primary care settings where the majority of leprosy patients are managed.

印度中部一个麻风病流行地区接受多药联用疗法的麻风病人中由多巴酚引起的溶血。
背景和目的:作为麻风病人MDT的一部分,多泼松引起的溶血早已得到认可。然而,这种副作用的频率和严重程度以及与之相关的因素尚未得到充分记录。我们计划确定接受多学科治疗的麻风病人中由他泼松诱发溶血的频率以及与之相关的各种风险因素:这是一项以医院为基础的回顾性分析,对象是恰蒂斯加尔邦一家三级医疗中心的 36 名已完成治疗、部分治疗或正在治疗的麻风病人:在 36 名患者中,83.3% 的患者血红蛋白较基线值(治疗前值)有所下降。33.3%的患者因血红蛋白显著下降而停用了多普松。我们发现,所有患者的平均血红蛋白浓度从 13.05(+/-1.8) g/dl 降至 11.8(+/-1.9) g/dl(P < 0.05),具有显著的统计学意义。根据我们的定义,共有25%的患者被确诊为多巴酚酮诱导的溶血病例:我们的研究结果表明,有必要将血液学检查纳入麻风病治疗方案,尤其是在基层医疗机构,因为大多数麻风病人都在基层医疗机构接受治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
7.10%
发文量
884
审稿时长
40 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信